HELP YOUR PATIENTS TAKE PART IN RESEARCH FROM HOME
WE MAKE IT EASY FOR ANYONE, ANYWHERE TO PARTICIPATE IN CLINICAL RESEARCH.
Benefits of the Science 37 Study Model
Remove barriers for patients to participate
Inaccessibility due to geography, lack of patient awareness and trust, and the inconvenience posed by site visits are the reasons why 80% of all clinical trials are delayed and fewer than 3% of eligible patients are able to volunteer to participate. This means that patients are waiting longer for better treatments. Science 37’s decentralized clinical trial model is a technology enabled service platform that allows patients to participate in clinical research studies from the comfort of home. Our trials are designed around the patient by leveraging mobile technology and telemedicine to connect participants with researchers and study staff, anytime and anywhere throughout the study.
Stay connected to your patients while they participate in a trial
Primary care clinicians and other local healthcare providers are an important trusted resource to their patients who are taking part in a research study. The ability to keep in touch during a research study helps to improve the patient’s experience. Science 37’s research staff stay connected to the participants and are always available to their local clinicians. Study tests and assessments may be conducted at locations within the patient’s local healthcare community whenever possible. From the beginning to the end of study participation, local providers can maintain a relationship with their patients who have joined a Science 37 research study.
Access study staff safely and securely
Patients can safely and securely participate in clinical research studies from the comfort of home through Science 37’s mobile technology platform, NORA®. NORA® is the software interface that connects patients to their study staff through a study smartphone. It is supported by telemedicine capabilities and highly trained clinical research staff. When seeking care with local clinicians, participants can notify study staff on the study smartphone at any time during the point of care. This can be especially helpful during an urgent care or emergency department visit. Our technology and service adhere to strict regulatory and compliance standards.
Restless Legs Syndrome Res...
Find a new path forward for adolescent restless legs syndrome through research.
Science 37 Raises $29M To Bring Clinical Trials Directly Into Patients...Series C growth round led by Glynn Capital Management with participation from GV (formerly Google Ventures), along with existing venture and strategic investors
A Potential Solution to More Diversity in Clinical TrialsScience 37's decentralized clinical trial model can reach more patients than traditional sites. This may be an answer to increasing access to new therapies for minorities and also to help ensure patient safety. Healthcare professionals can all help to raise awareness about clinical research.
Science 37 and Sanofi Introduce a New PartnershipWithout clinical trials, new medicine may never make it from the research lab to patients in need. These carefully designed studies can provide important data that include proper dosage, benefit to patients, and potential side effects. There is a growing challenge, however, in finding appropriate participants, especially for treatments that target highly specific conditions affecting narrower patient populations. Right now, there are more than 40,000 clinical studies recruiting patients in the U.S. alone, with some…
Playing for the Long Term – NYT DealBook Conference(Science Launch with Dr. Noah Craft Co-founder and CEO of Science 37 - courtesy of New York Times DealBook Conference) Two weeks ago, I was presented with a great opportunity to speak amongst some very distinguished individuals at the New York Times DealBook Conference. In a modern world of instant gratification, this conference gave some innovators the chance to come together and speak of long term visions or goals. At Science 37, we're combining technology advances that…
Science 37 and LA BioMed launch telemedicine substudy arm of global PE...LA BioMed and Science 37 have launched their first collaborative clinical research trial and enrolled patients in the first-ever virtual, networked clinical trial using telemedicine to monitor the effects of an infusion medication. The research study will compare the effects of rituximab with another medication called mycophenolate mofetil in treating adults with active pemphigus vulgaris (PV). Pemphigus vulgaris is an auto-immune skin condition that causes your skin to form blisters. LA Biomed is one of…